What happened Last week, President Biden signed the Inflation Reduction Act (IRA), a slimmed down version of the Build Back Better plan. It is a major piece of legislation that provides $485bn to fund climate change and decarbonisation investments ($386bn) and expand healthcare access ($98bn). Funding will come from prescription drug savings ($322bn) and a 15 per cent corporate minimum tax ($313bn), as well as expanded tax collection enforcement and a 1 per cent tax on corporate share buybacks, with total funding at $790bn. The difference of $305bn will be used to reduce the federal deficit, on a back-end loaded schedule.
The key climate provisions in the IRA include extension and expansion of energy production tax credits for low-carbon energy sources (e.g. wind, solar, nuclear and hydrogen) and increased support for electric vehicles. On healthcare, the IRA extends ACA (Affordable Care Act) provisions for three more years and allows the government for the first time to negotiate Medicare drug pricing.
To overcome Senator Manchin’s long-standing opposition to the bill, concessions to the fossil fuel industry were included, notably streamlined permitting for oil and gas drilling on federal lands in the US Gulf of Mexico and Alaska.
Implications From a fiscal perspective, we don’t expect the plan to have a heavy impact on either US growth or inflation over the next two to three years, as the package was designed to have a fiscal impact of less than 0.1 per cent of GDP before 2027. As Chart 1 shows, this deficit reduction will be mostly back-end loaded.
The longer-term macro impacts will derive from support for decarbonisation and a targeted 40 per cent reduction in GHG emissions versus 2005 levels (Chart 2). The Congressional Budget Office (CBO) projects up to a 1 per cent headwind to US GDP by 2030 from climate change, so if the policy succeeds in combination with global efforts, the benefit would arise through mitigation.
US consumers may see some relief on energy and healthcare costs, if a) domestic oil and gas production increases due to easier permitting and b) significant reductions in drug pricing are achieved.
Outlook From an economic perspective, as noted, near-term growth and inflation impacts will be muted. From a policy lens and looking towards the November midterms, the unexpected revival and passing of a major climate change and drug-pricing law, together with recent political and Supreme Court developments and some abatement in gasoline inflation, have shifted the odds of retaining the Senate slightly back to the Democrats. However, Republicans remain heavily favoured to take the House of Representatives. From a fiscal policy perspective, this would imply Congressional gridlock after 2022, constraining further action by the White House on tax reform and longer-term spending on social and environmental programmes.
Asset allocation We remain defensive on high risk of recession in Europe and the US and a halting recovery in China due to its zero-Covid policy. In the US, we continue to anticipate a “catch down” of hard data to a very challenging soft data picture and continued Fed hawkishness, for now.
Look out for more on how this bill will boost US climate investing from Fidelity’s investment team.
Important Information
This document is for Investment Professionals only and should not be relied on by private investors.
This document is provided for information purposes only and is intended only for the person or entity to which it is sent. It must not be reproduced or circulated to any other party without prior permission of Fidelity.
This document does not constitute a distribution, an offer or solicitation to engage the investment management services of Fidelity, or an offer to buy or sell or the solicitation of any offer to buy or sell any securities in any jurisdiction or country where such distribution or offer is not authorised or would be contrary to local laws or regulations. Fidelity makes no representations that the contents are appropriate for use in all locations or that the transactions or services discussed are available or appropriate for sale or use in all jurisdictions or countries or by all investors or counterparties.
This communication is not directed at, and must not be acted on by persons inside the United States and is otherwise only directed at persons residing in jurisdictions where the relevant funds are authorised for distribution or where no such authorisation is required. Fidelity is not authorised to manage or distribute investment funds or products in, or to provide investment management or advisory services to persons resident in, mainland China. All persons and entities accessing the information do so on their own initiative and are responsible for compliance with applicable local laws and regulations and should consult their professional advisers.
Reference in this document to specific securities should not be interpreted as a recommendation to buy or sell these securities, but is included for the purposes of illustration only. Investors should also note that the views expressed may no longer be current and may have already been acted upon by Fidelity. The research and analysis used in this documentation is gathered by Fidelity for its use as an investment manager and may have already been acted upon for its own purposes. This material was created by Fidelity International.
Past performance is not a reliable indicator of future results.
This document may contain materials from third-parties which are supplied by companies that are not affiliated with any Fidelity entity (Third-Party Content). Fidelity has not been involved in the preparation, adoption or editing of such third-party materials and does not explicitly or implicitly endorse or approve such content.
Fidelity International refers to the group of companies which form the global investment management organization that provides products and services in designated jurisdictions outside of North America Fidelity, Fidelity International, the Fidelity International logo and F symbol are trademarks of FIL Limited. Fidelity only offers information on products and services and does not provide investment advice based on individual circumstances.
Issued in Europe: Issued by FIL Investments International (FCA registered number 122170) a firm authorised and regulated by the Financial Conduct Authority, FIL (Luxembourg) S.A., authorised and supervised by the CSSF (Commission de Surveillance du Secteur Financier) and FIL Investment Switzerland AG. For German wholesale clients issued by FIL Investment Services GmbH, Kastanienhöhe 1, 61476 Kronberg im Taunus. For German Institutional clients issued by FIL (Luxembourg) S.A., 2a, rue Albert Borschette BP 2174 L-1021 Luxembourg.
ED22 - 151
